The PSInSAR satellite technique used to observe the gradual sinking of Uttarakhand's Joshimath town is a powerful remote sensing tool capable of measuring and monitoring displacements in the Earth's surface over time.
Dulquer may be good looking but how long can you watch him with a cigarette in his mouth, giving that deadpan expression, wonders Divya Nair.
The B.1.640.2 variant has been reported by researchers at institute IHU Mediterranee Infection in at least 12 cases, and has been linked to travel to African country Cameroon.
Covaxin is being developed by Bharat Biotech jointly with the Indian Council of Medical Research (ICMR)- National Institute of Virology (NIV). The Phase III human clinical trials of Covaxin began mid-November, targeted to be done in 26,000 volunteers and it is the country's first and only Phase III efficacy study for a COVID-19 vaccine, a press release from the vaccine maker said on Saturday night.
The fourth wave of the Covid-19 pandemic in India may start around June 22 and peak from mid to late August, a modelling study by researchers at the Indian Institute of Technology-Kanpur suggests.
The third wave of the COVID-19 pandemic in India may peak by February 3, 2022, claims a modelling study by researchers at Indian Institute of Technology Kanpur.
Two doses of Pfizer and AstraZeneca COVID-19 vaccines generate lower levels of antibodies against the Omicron variant of coronavirus, according to a study which suggests that those previously infected or vaccinated may be at an increased risk of infection.
It is certain that the Chinese government was 'under-prepared' as it decided to end its zero-COVID policy abruptly after people held protests across the country, The Hong Kong Post reported.
'The ICMR and Biological E Limited, Hyderabad, have developed highly purified antisera (raised in animals) for prophylaxis and treatment of COVID-19,' the apex health research body said on Thursday. The 'antisera' is yet to undergo human clinical trials to establish its safety and efficacy and Drugs Controller General of India would be approached soon in this regard, Dr Samiran Panda, the head of epidemiology and communicable diseases at the ICMR said.
Cloned journals have become more rampant in the post-pandemic world.
If that outcome were to happen, the Modi government would be responsible for presiding over a self-inflicted national catastrophe.
Omicron can evade the immune protection conferred by COVID-19 vaccines and natural infection, according to a peer-reviewed study which also suggests that the new variant of coronavirus is completely resistant to antibody therapies in use today.
These stocks offer the best combination of maximum 'buy' recommendations from brokerages and share price upside over the next 12 months.
Safety and Efficacy results from the final analysis will be available in June, and the final report will be submitted to a peer-reviewed publication.
This is a film you should watch even if you aren't a comic book person at all.
Bharat Biotech recruited 13,000 participants for the Phase-3 clinical trial of Covaxin. This is one of the largest efficacy trials held in the country.
An Indian student has claimed that he was disqualified from the London School of Economics (LSE) Students' Union elections as a result of a deliberately orchestrated smear campaign because of his Indian and Hindu identity.
In a virtual conference from Moscow, Dmitriev said Sputnik V is not only 'one of the most effective' but also among the 'affordable' vaccines in the world.
Antibodies produced by two doses of mRNA vaccines against the original and early variants of the SARS-CoV-2 virus wane substantially over time, and offer essentially no protection against Omicron, according to a study that highlights the importance of a booster dose.
They have named this unique cluster of virus population as 'Clade A3i' found in 41 per cent of the genome sequenced in India.
The K-shaped economic recovery in India from the pandemic slowdown shows in corporate results as well. The automobile sector, which represents big-ticket consumption, continues to do well and has increased its share in corporate revenues and profits while fast-moving consumer goods (FMCG) companies that sell low-ticket consumer goods are struggling with poor sales and earnings growth. The share of the automobile sector, including makers of auto ancillaries, in corporate net sales rose to a 10-quarter high of 10.05 per cent during July-September 2023 (Q2FY24) from 8.94 per cent a year earlier and 9.75 per cent in Q1FY24.
Vaccine major Bharat Biotech on Wednesday said its COVID-19 vaccine, Covaxin, has demonstrated an interim vaccine efficacy of 81 per cent in the Phase 3 clinical trials.
All those of us who care about books should welcome the appointment, as head of the Indian Council of Historical Research, of Yellapragada Sudarshan Rao. This is not because Rao has so far distinguished himself as a writer about "history and tourism management", which is the department of Kakatiya University in Warangal he headed before retiring to head an Rashtriya Swayamsevak Sangh-backed project to "write history from a nationalist perspective and popularise Sanskrit", two aims which naturally go together for the RSS.
Among the Sensex stocks, Larsen & Toubro rose the most by 3.96 per cent after the company announced a major project win in the Middle East. HDFC, HDFC Bank, Sun Pharma, ITC, HUL, Titan, TCS, HCL Tech, Asian Paints, Bajaj Finance, Infosys and Tata Steel were among the major gainers.
Chandrayaan-2 was launched on July 22, 2019 and inserted into the lunar orbit on August 20, exactly one year ago.
The vaccine induced robust binding and neutralising antibody responses which were comparable to those observed in the convalescent serum collected from patients who had recovered from COVID-19, according to the findings which have appeared on medRxiv, a preprint server.
RBI's previous monetary policy was announced on September 29.
A new variant of SARS-CoV-2, the virus which cause COVID-19, has been detected in South Africa and many other countries globally which could be more transmissible and evade protection provided by vaccines, according to study.
'There is a need for an innovation sandbox where the PSBs can collaborate and then they can do their own innovation on top of it.'
'Viral infections rise in winter and better care needs to be taken in the next few months.'
The study, which was conducted on more than 100 healthcare workers at three centres in India including Sir Ganga Ram Hospital, found that the B.1.617.2 Delta variant not only dominates vaccine-breakthrough infections with higher respiratory viral loads compared to non-Delta infections (Ct value of 16.5 versus 19) but also generates greater transmission among the fully vaccinated HCWs.
Why a new study suggests you wear a face mask when you speak to anyone.
"The unsound analysis of the said article is based on the extrapolation of data without any epidemiological evidence," the ministry said, adding the studies used by the magazine to estimate the mortality are not validated tools for determining the death rate of any country or region.
The rupee is expected to remain volatile in the new financial year.
The efficacy of the vaccine, developed by the Gamalaya Centre, was demonstrated on the basis of a first interim analysis obtained 21 days after the first injection.
Bank of Baroda Q4 results: Key brokerages have raised their target prices on Bank of Baroda after the state-owned lender posted better-than-expected March quarter (Q4FY23) results. Analysts now see up to 29 per cent upside in the stock from a one-year perspective as they believe BoB is well-placed among the large public banks with nearly all key business metrics moving closer to the top-tier banks. Valuations, too, remain attractive despite steady strong quarterly performances.
A trial has shown that plasma therapy does not reduce mortality or prevent progression of COVID-19.
In FY23, the State Bank of India (SBI) reported a 57.4 per cent jump in its net profit to Rs 55,684.17 crore. But the chairman of the country's largest bank, Dinesh Khara's annual pay for this creditable performance was just Rs 37 lakh (his peers at state-run banks are no better off). Look at his private bank rivals - most pocketed in excess of Rs 7 crore annually - plus stock options.
The institute expects to complete both, phase-2 and 3 trials in India by the end of this year.
What was the need to fictionalise a series on real events that were far more horrific because they were real? asks Vaihayasi Pande Daniel.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances